Clinical studies have shown the efficacy of agents like pazopanib and intravenous bevacizumab in treating advanced HBs, including VHL-associated and recurrent cases, demonstrating tumor reduction, edema reduction, and improved survival (18–22). The gene discussed is VHL; the disease is neoplasm.